Jain Ruhee, Seebold Rob, Weiser Jonathan, Smith Emma, Stevens Andrea, Monga Neerav, Bevans Katherine, Pagano Matthew, Pascoe Katie
Johnson & Johnson, Raritan, NJ, USA.
Buzzback, London, UK.
Future Oncol. 2025 Jul;21(16):2053-2066. doi: 10.1080/14796694.2025.2510890. Epub 2025 Jun 2.
Patients with metastatic castration-resistant prostate cancer (mCRPC) and caregivers were surveyed to understand their attitudes, emotions, and experiences with the disease, its treatments, and their willingness to explore genetic testing.
A non-interventional, cross-sectional, online, quantitative-qualitative survey was conducted from 17-February to 9March 2022 among patients (≥21-years old) with mCRPC (diagnosis for ≥3-months) and caregivers.
A total of 221 patients with mCRPC and 159 caregivers from USA, France, Germany, Canada, Spain, China, and Brazil were surveyed. mCRPC impacts mood, emotional and mental health (50-77%), sleep (48-68%), career goals (48-80%), and social activities (46-65%). Primary symptoms/side effects are urination issues (trouble urinating: 33-60%; painful/burning urination: 32-50%, frequent urination: 27-50%) and sexual dysfunction (lower libido: 10-57%), which impact romantic relationships. Caregivers often spouses or partners, provide practical, financial, and emotional support, averaging 11 hours/week of providing care. Patients face high treatment and pill burden (7-12 pills/day) and prefer simpler treatment regimens. Hope motivates patients and genetic testing is one such avenue of hope.
mCRPC is a life-changing diagnosis with physical, psychological, and financial burdens. By encouraging early genetic testing and fostering patient-centered conversation, HCPs can provide personalized care for optimized treatment outcomes in mCRPC.
对转移性去势抵抗性前列腺癌（mCRPC）患者及其照护者进行调查，以了解他们对该疾病、其治疗方法的态度、情绪和经历，以及他们探索基因检测的意愿。
于2022年2月17日至3月9日对年龄≥21岁、mCRPC诊断≥3个月的患者及其照护者进行了一项非干预性、横断面、在线的定量-定性调查。
共对来自美国、法国、德国、加拿大、西班牙、中国和巴西的221例mCRPC患者和159名照护者进行了调查。mCRPC会影响情绪、情感和心理健康（50%-77%）、睡眠（48%-68%）、职业目标（48%-80%）和社交活动（46%-65%）。主要症状/副作用是排尿问题（排尿困难：33%-60%；尿痛/排尿烧灼感：32%-50%，尿频：27%-50%）和性功能障碍（性欲减退：10%-57%），这些会影响恋爱关系。照护者通常是配偶或伴侣，提供实际、经济和情感支持，平均每周提供11小时的照护。患者面临较高的治疗和服药负担（每天7-12片药），更喜欢更简单的治疗方案。希望激励着患者，基因检测是希望的途径之一。
mCRPC是一种改变生活的诊断，会带来身体、心理和经济负担。通过鼓励早期基因检测并促进以患者为中心的对话，医疗保健人员可以为mCRPC患者提供个性化护理，以优化治疗效果。
